Sodium–glucose cotransporter 2 inhibition through henagliflozin ameliorates cognitive impairment in patients with type 2 diabetes
Henagliflozin treatment was independently associated with improvements in Montreal Cognitive Assessment scores and plasma phosphorylated tau181 levels, indicating significant beneficial effects on cognitive impairment in patients with type 2 diabetes.
Authors
- Lei Xie (ORCID: https://orcid.org/0000-0002-6086-4607)
- Xuefeng Yu (ORCID: https://orcid.org/0000-0003-3961-9321)
- Jialu Xu (ORCID: https://orcid.org/0000-0002-1801-7682)
- Xiaoli Shi (ORCID: https://orcid.org/0000-0002-2904-1784)
- Juan Chen (ORCID: https://orcid.org/0000-0001-7515-5072)
- Shujun J. Zhang (ORCID: https://orcid.org/0000-0001-6139-6887)
- Fen Wang (ORCID: https://orcid.org/0000-0002-4876-710X)
- Tao Jing (ORCID: https://orcid.org/0000-0002-1755-9578)
- Yan Yang (ORCID: https://orcid.org/0000-0001-8146-8040)
- Xiaoqing Song (ORCID: https://orcid.org/0000-0003-0349-896X)
- Delin Ma (ORCID: https://orcid.org/0000-0001-5039-7251)
Institutions
- Tongji Hospital (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- Journal of Diabetes Investigation
- Published
- 2024-09-10
- DOI
- https://doi.org/10.1111/jdi.14306
- Citations
- 4
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.43